AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel’s Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.

SAN MATEO, Calif., July 8 /PRNewswire/ — After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.

On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey to measure immediate physician awareness and reactions to the panel recommendation. In a brief on-line survey of 52 cardiologists and 51 endocrinologists AlphaDetail found:

   — Unaided, about 40% of physicians mentioned CV risk associated with      diabetes medications as the most important development in diabetes      treatment from the past month.   — When prompted, half of physicians indicated they had heard about the      FDA panel recommendation to require cardiovascular safety trials for      new diabetes medications — only a day after the news was announced.   — Although most physicians from both specialties support the      recommendation, twice as many cardiologists (33%) vs. endocrinologists      (16%) agree strongly with it.          — However, 22% of endocrinologists disagree with the             recommendation primarily because they believe it would stifle             innovation and delay the availability of important new             therapies.   — Physicians disagree on the most appropriate implementation of the FDA      panel recommendation — two CV safety trials vs. only one trial.          — However, more physicians believe that the two trial             implementation is the most appropriate.   — Even so, a segment of physicians (25% of cardiologists and 37% of      endocrinologists) would support prescribing a new diabetes therapy that      is highly efficacious but has CV risk to patients that have no CV risk      factors other than diabetes.          — Physicians have to make a trade-off between controlling diabetes             and preventing other diabetes complications vs. preventing CV             risk.    

To learn more about this study, please contact Bob Latshaw at Bob.Latshaw@alphadetail.com or (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us answer our client’s most challenging questions.

AlphaDetail, Inc.

CONTACT: Bob Latshaw, Vice President of Sales of AlphaDetail, Inc.,+1-215-259-5601, Bob.Latshaw@alphadetail.com

Web site: http://www.alphadetail.com/